fluconazole has been researched along with Pulmonary Consumption in 14 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " She was then diagnosed as disseminated cryptococcosis and treated with liposomal amphotericin B and fluconazole successfully." | 3.83 | [A pediatric case of HIV who diagnosed by virtue of disseminated cryptococcus infection]. ( Acar, M; Ağaçfidan, A; Aktürk, H; Beka, H; Hançerli Törün, S; Karagöz, N; Salman, N; Somer, A; Sütçü, M; Yekeler, E, 2016) |
| "Neuromeningeal cryptococcosis and pulmonary tuberculosis are respectively serious mycotic and bacterial infections occurring in a subject regardless of its HIV serological status." | 1.72 | [Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali]. ( Alle Akakpo, AE; Cissoko, Y; Dao, S; Konaté, I; Loua, OO; Ouedraogo, D; Soumaré, M, 2022) |
| "Fluconazole was administered and the computed tomography findings improved." | 1.56 | Pulmonary Cryptococcosis in a Nurse Initially Suspected of Having Pulmonary Tuberculosis. ( Ikeda, H; Kasai, H; Ogawa, H; Shinozaki, T; Urushibara, T, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Loua, OO | 1 |
| Alle Akakpo, AE | 1 |
| Ouedraogo, D | 1 |
| Cissoko, Y | 1 |
| Soumaré, M | 1 |
| Konaté, I | 1 |
| Dao, S | 1 |
| Monzani, V | 1 |
| Córdoba, S | 1 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 1 |
| Szusz, W | 1 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Ogawa, H | 1 |
| Urushibara, T | 1 |
| Kasai, H | 1 |
| Ikeda, H | 1 |
| Shinozaki, T | 1 |
| Johnson, K | 1 |
| Dhamrah, U | 1 |
| Amin, A | 1 |
| Masci, J | 1 |
| Acar, M | 1 |
| Sütçü, M | 1 |
| Aktürk, H | 1 |
| Hançerli Törün, S | 1 |
| Karagöz, N | 1 |
| Beka, H | 1 |
| Yekeler, E | 1 |
| Ağaçfidan, A | 1 |
| Salman, N | 1 |
| Somer, A | 1 |
| Bereznikov, AV | 1 |
| Mordyk, AV | 1 |
| Lysov, AV | 1 |
| Konev, VP | 1 |
| Kingkaew, N | 1 |
| Sangtong, B | 1 |
| Amnuaiphon, W | 1 |
| Jongpaibulpatana, J | 1 |
| Mankatittham, W | 1 |
| Akksilp, S | 1 |
| Sirinak, C | 1 |
| Nateniyom, S | 1 |
| Burapat, C | 1 |
| Kittikraisak, W | 1 |
| Monkongdee, P | 1 |
| Varma, JK | 1 |
| Nuevo, JA | 1 |
| Hijano, A | 1 |
| Eimil, M | 1 |
| Valdivia, A | 1 |
| Candel, FJ | 1 |
| Núñez, MJ | 1 |
| Roca, V | 1 |
| MESCOLINI, G | 1 |
| Kul'ko, AB | 1 |
| Mitrokhin, SD | 1 |
| Moroz, AM | 1 |
| Onizuka, O | 2 |
| Kawano, M | 1 |
| Takikawa, S | 1 |
| Sugihara, R | 1 |
| Ando, H | 1 |
| Peloquin, CA | 1 |
| Nitta, AT | 1 |
| Burman, WJ | 1 |
| Brudney, KF | 1 |
| Miranda-Massari, JR | 1 |
| McGuinness, ME | 1 |
| Berning, SE | 1 |
| Gerena, GT | 1 |
| Bani-Sadr, F | 1 |
| Hoff, J | 1 |
| Chiffoleau, A | 1 |
| Allavena, C | 1 |
| Raffi, F | 1 |
| Yoshimatsu, T | 1 |
| Matsumoto, T | 1 |
| Tsuda, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fluconazole and Pulmonary Consumption
| Article | Year |
|---|---|
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
13 other studies available for fluconazole and Pulmonary Consumption
| Article | Year |
|---|---|
[Neuromeningeal cryptococcosis in an HIV-negative patient with pulmonary tuberculosis in the Infectious and tropical diseases department of the University teaching hospital Point G of Bamako, Mali].
Topics: Acetaminophen; Adolescent; AIDS-Related Opportunistic Infections; Communicable Diseases; Cryptococco | 2022 |
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
Pulmonary Cryptococcosis in a Nurse Initially Suspected of Having Pulmonary Tuberculosis.
Topics: Adult; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cryptococcosis; Delayed Diagnosis; Female; Flucon | 2020 |
Case Report: A Great Mimicker of Neoplasm: Pulmonary Cryptococcosis in an Immunocompetent Host After High-Altitude Descent.
Topics: Aged, 80 and over; Altitude; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Diagnosis, | 2021 |
[A pediatric case of HIV who diagnosed by virtue of disseminated cryptococcus infection].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Retroviral Agents; Antifungal Agents; Ch | 2016 |
[Antibiotic-associated diarrheas in phthisiatric care: standardization of their diagnosis, treatment, prevention, examination of health care quality].
Topics: Anti-Bacterial Agents; Antidiarrheals; Antifungal Agents; Diarrhea; Fluconazole; Follow-Up Studies; | 2008 |
HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Cohort Studies | 2009 |
[Candida esophagitis in a non-immunosuppressed patient].
Topics: Adult; Antifungal Agents; Antitubercular Agents; Candidiasis; Esophagitis; Female; Fluconazole; Huma | 2002 |
[Topography and morphology of zonal pulmonary densities caused by tuberculous primary infection (forms with favorable evolution); clinico-pathogenetic and therapeutic considerations].
Topics: Fluconazole; Humans; Lung; Radiography; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Respiratory tract mycotic infection in phthisiological practice: species composition and susceptibility of the Candida clinical isolates to antifungal agents].
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Female; Fluconazole; Humans; Itrac | 2005 |
[Pharmacokinetics of transbronchially injected flconazole in pulmonary aspergillosis].
Topics: Aged; Aspergillosis; Bronchi; Epithelium; Female; Fluconazole; Humans; Injections, Intralesional; Lu | 1995 |
[Severe hypercalcemia in a patient treated with fluconazole and rifampicin].
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antifungal Agents; Female | 1998 |
[Percutaneous instillation of fluconazole in the treatment of pulmonary aspergilloma].
Topics: Administration, Cutaneous; Aged; Aspergillosis; Female; Fluconazole; Humans; Injections, Intralesion | 1991 |